



**Thursday, December 10th, 2015**  
**7:15 a.m. to 8:15 a.m.**  
**Cannon Health Building**  
**Room 125**

**Board Members Present:**

Jay Aldus, D.D.S  
Ben Berrett, Pharm.D.  
Jennifer Brinton, M.D., Board Chair  
Neal Catalano, Pharm.D.  
Holly Gurgle, Pharm.D.  
Steve Lore, M.D.

Kumar Shah, M.Sc., P.Eng.  
Susan Siegfried, M.D.  
Katherine Smith, Pharm.D.  
Michael Symond, M.D.  
Keith Tolman, M.D.

**Board Members Excused:**

n/a

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Chad Hope, Pharm.D.  
Robyn Seely, Pharm.D.  
Bryan Larson, Pharm.D.

Merelynn Berrett, R.N.  
Heather Santacruz, R.N.  
Alyssa Pitts, R.N.

**Other Individuals Present:**

Gary Oderda, University of Utah  
Joanita Lake, University of Utah  
Eliot Brinton, Utah Lipid Center  
Cody Ball, Select Heath  
Mindy Peterson, Healthy U  
Laura Britton, Healthy U  
Lynsey Spence, State Auditor

Greg Gittus, Alkermes  
Paul Skodny, Amgen  
Charissa Anne, Johnson & Johnson  
Chris DeSimone, Agerion  
Lori Howarth, Bayer

---

**Meeting conducted by Jennifer Brinton, M.D.**

---

- 1. Welcome** – Jennifer Brinton opened the meeting
- 2. Housekeeping** – Robyn Seely reminded Board members and guests to sign in. Robyn Seely then called for a review of September's meeting minutes. Kumar Shah noted a typo under Housekeeping. "Kumar Shah has agreed to serve another *year* on the DUR board" should read "Kumar Shah has agreed to serve another *term* on the DUR board".
- 3. Approval of November Meeting Minutes** – Minutes had not yet been prepared so approval was postponed until January.

4. **Clinical Presentation: Topical Lidocaine Products** – Melissa Archer, Pharm.D. from the University of Utah DRRC presented drug information including studies, side effects, indications and other information about the agents. Data was also presented about the utilization of the drugs in the Utah Medicaid fee-for-service population.
5. **Public Comment** – none
6. **Board Discussion** – *Note that the audio recording of the meeting failed and the following is a brief description of major points made.*
  - a. **Toxicity and Adverse Reactions**
    - 1) Melissa Archer noted that some patients apply topical lidocaine creams, ointments, jellys, etc to large skin surface areas and then occlude them with plastic wrap for an extended period of time. This is incorrect use and can cause toxicity. Holly Gurgle stated that some prescribers resort to incorrect use of topical creams, ointments, jellys, etc when lidocaine patches are not approved by third party payors.
    - 2) Robyn Seely noted that a minimum age requirement should be established for oral viscous lidocaine to reduce incidences of choking in pediatric patients.
  - b. **Pain Origins, Pain Types and Concurrent Pain Medications**
    - 1) Susan Siegfried cited evidence that topical lidocaine is not an effective treatment for nociceptive pain. Steve Lore noted that topical lidocaine patches serve an important role in his hospice practice, for many types of pain. Melissa Archer confirmed probable efficacy of topical lidocaine on other types of pain, citing current trials.
    - 2) Mike Symond noted that a solution of oral viscous lidocaine and is used in the ED setting as a diagnostic tool when a patient presents with abdominal pain.
7. **Meeting Closure** – Mike Symond made a motion to close the meeting. Neal Catalano seconded the motion. All in favor.

The next DUR Board meeting is scheduled for Thursday, November 12<sup>th</sup>.

Minutes prepared by Robyn Seely, Pharm.D.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)